Laboratoire Theramex
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
14
Drug Approvals
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Minimal Effective Dose of Nomegestrol Acetate Inhibiting the Ovulation in Women Receiving Estradiol
- First Posted Date
- 2011-05-27
- Last Posted Date
- 2011-05-27
- Lead Sponsor
- Theramex
- Target Recruit Count
- 38
- Registration Number
- NCT01361958
News
Scottish Health Authority Approves Theramex's Abaloparatide for High-Risk Osteoporosis Treatment
The Scottish Medicines Consortium has recommended Theramex's Eladynos (abaloparatide) for treating osteoporosis in postmenopausal women at very high risk of fracture through NHS Scotland.
Daré Bioscience and Theramex Partner to Develop Novel Biodegradable Contraceptive Implant
Daré Bioscience and Theramex have entered into a co-development agreement for Casea S, a first-in-category biodegradable contraceptive implant designed to last 18-24 months.
Linzagolix (Yselty) Receives European Commission Approval for Endometriosis
Linzagolix (Yselty), a GnRH antagonist developed by Kissei, has been approved by the European Commission for treating endometriosis.
Theramex Launches Linzagolix (Yselty) for Uterine Fibroids in Europe
Theramex has launched Yselty (linzagolix), a GnRH receptor antagonist developed by Kissei, in Germany for treating moderate to severe uterine fibroids.
NICE Approves Eladynos for Postmenopausal Osteoporosis, But NHS Diagnostic Gaps Pose Access Challenges
NICE has approved Eladynos (abaloparatide) for routine NHS use in postmenopausal women at high risk of osteoporotic fractures, potentially benefiting 14,000 patients in England.